Law Offices of Howard G. Smith reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Hims & Hers Health, Inc ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Limited edition Meta Quest 3S Xbox bundle features custom Xbox-themed headset and controllers, offering cloud gaming as part ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, ...

Jenny Mollen, Jason Biggs’ wife, shared how microdosing GLP1 medication led to an ER visit and raised concerns about mental health effects ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Plus: Why Krispy Kreme left McDonald's, Boeing's latest woes, the potential Shell-BP merger, Bumble's stumble, Nvidia's cloud ...

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and ...